Fred Shane serves as Managing Partner (also listed as Managing Director) at Axil Capital. See contact routes.
Fred Shane serves as Managing Partner (also listed as Managing Director) at Axil Capital, a Tokyo-based venture firm he co-founded in 2017, where he heads the global investment team and manages its portfolio. His investment thesis targets early-stage to crossover-stage companies globally within the biomedical and healthcare technology sectors, including biopharmaceuticals, medical devices, digital health, and healthcare services. Prior to Axil, Shane was a Director at Mizuho Securities and helped establish biotech investment operations at Marubeni USA, gaining deep lifecycle deal experience. Axil Capital’s portfolio includes notable companies such as GEXVal, Eurus Therapeutics, and Cell Box Lab, reflecting its focus on life sciences innovation. The firm’s mission emphasizes building commercially viable enterprises with long-term impact on medicine while generating investor returns. No public writing or distinctive point-of-view statements by Shane are documented in available sources. Check sizes and lead/follow behavior are not specified in the search results.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Tokyo when building a target list.
Investors like Fred Shane · Full investor directory · Investor access · Company funding database